WO2001036627A3 - Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders - Google Patents

Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders Download PDF

Info

Publication number
WO2001036627A3
WO2001036627A3 PCT/IL2000/000763 IL0000763W WO0136627A3 WO 2001036627 A3 WO2001036627 A3 WO 2001036627A3 IL 0000763 W IL0000763 W IL 0000763W WO 0136627 A3 WO0136627 A3 WO 0136627A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
acetylcholinesterase
muscular
pharmaceutical compositions
neuromuscular disorders
Prior art date
Application number
PCT/IL2000/000763
Other languages
French (fr)
Other versions
WO2001036627A2 (en
Inventor
Hermona Soreq
Shlomo Seidman
Original Assignee
Yissum Res Dev Co
Hermona Soreq
Shlomo Seidman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Hermona Soreq, Shlomo Seidman filed Critical Yissum Res Dev Co
Priority to AU15461/01A priority Critical patent/AU1546101A/en
Publication of WO2001036627A2 publication Critical patent/WO2001036627A2/en
Publication of WO2001036627A3 publication Critical patent/WO2001036627A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes

Abstract

The present invention relates to a pharmaceutical composition for the treatment and/or prevention of a progressive neuromuscular disorder, and for use in decreasing muscle fatigue, comprising low concentrations of a synthetic antisense oligonucleotide targeted to the common coding domain of acetylcholine esterase (AChE) mRNA. The present invention further relates to a novel method for the diagnosis of progressive neuromuscular disorders.
PCT/IL2000/000763 1999-11-16 2000-11-16 Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders WO2001036627A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU15461/01A AU1546101A (en) 1999-11-16 2000-11-16 Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL132972 1999-11-16
IL13297299A IL132972A0 (en) 1999-11-16 1999-11-16 Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders

Publications (2)

Publication Number Publication Date
WO2001036627A2 WO2001036627A2 (en) 2001-05-25
WO2001036627A3 true WO2001036627A3 (en) 2001-10-04

Family

ID=11073493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2000/000763 WO2001036627A2 (en) 1999-11-16 2000-11-16 Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders

Country Status (3)

Country Link
AU (1) AU1546101A (en)
IL (1) IL132972A0 (en)
WO (1) WO2001036627A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328346B2 (en) 2010-11-12 2016-05-03 The General Hospital Corporation Polycomb-associated non-coding RNAs

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143379A (en) 2001-05-24 2013-11-28 Yissum Res Dev Co Antisense oligonucleotide against the r isophorm of human ache and uses thereof
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
JP2015523854A (en) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Compositions and methods for modulating SMN gene family expression
AP2014008100A0 (en) 2012-05-16 2014-12-31 Gen Hospital Corp Compositions and methods for modulating hemoglobingene family expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
WO2013173608A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating mecp2 expression
US10174323B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating ATP2A2 expression
AU2013262656A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating UTRN expression
CA2966044A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
WO2016149455A2 (en) 2015-03-17 2016-09-22 The General Hospital Corporation The rna interactome of polycomb repressive complex 1 (prc1)
EP3969587A4 (en) * 2019-05-13 2023-02-15 The Trustees of The University of Pennsylvania Compositions and methods of acetylcholine receptor chimeric autoantibody receptor cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021202A1 (en) * 1992-04-15 1993-10-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them
WO1998026062A2 (en) * 1996-12-12 1998-06-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them
US5932780A (en) * 1994-02-28 1999-08-03 Yissum Research Development Company Of Hebrew University Of Jerusalem Transgenic non-human animal assay system for anti-cholinesterase substances

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021202A1 (en) * 1992-04-15 1993-10-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them
US5932780A (en) * 1994-02-28 1999-08-03 Yissum Research Development Company Of Hebrew University Of Jerusalem Transgenic non-human animal assay system for anti-cholinesterase substances
WO1998026062A2 (en) * 1996-12-12 1998-06-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEIDMAN S. ET AL.: "Antisense technologies have a future fighting neurodegenerative diseases", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, vol. 9, August 1999 (1999-08-01), pages 333 - 340, XP000984531 *
TALMA BRENNER ET AL: "Antisense approach to the anticholinesterase management of myasthenia gravis.", JOURNAL OF AUTOIMMUNITY, no. SUPPL., 1999, 2nd International Congress on Autoimmunity;Tel Aviv, Israel; March 7-11, 1999, pages 22, XP000986370, ISSN: 0896-8411 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328346B2 (en) 2010-11-12 2016-05-03 The General Hospital Corporation Polycomb-associated non-coding RNAs

Also Published As

Publication number Publication date
WO2001036627A2 (en) 2001-05-25
AU1546101A (en) 2001-05-30
IL132972A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
WO2001036627A3 (en) Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
PL347469A1 (en) Use of certain drugs for treating nerve root injury
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
WO2003013437A3 (en) Compositions and methods for the prevention and treatment of huntington's disease
WO2006133955A8 (en) Adamts13-comprising compositions having thrombolytic activity
WO2004004661A3 (en) Boroproline compound combination therapy
WO2001073002A3 (en) Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
WO2001092512A3 (en) Targeted chromosomal genomic alterations in plants using modified single stranded oligonucleotides
CA2458806A1 (en) Antisense oligonucleotide against human ache and uses thereof
WO2004108157A8 (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
CA2250372A1 (en) 6-phenylpyridyl-2-amine derivatives
ID28916A (en) TREATMENT OF BILLS AND BEHAVIOR RELATING TO BILLS
PL357822A1 (en) Compositions and methods for improving vascular health
WO2002053187A3 (en) Methods and transdermal compositions for pain relief
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
WO2006001877A3 (en) Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
AU4331400A (en) Neurotrophic substituted pyrimidines
PL316313A1 (en) Naphtyloamides as agents acting on a central nerve system
MXPA06000705A (en) Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders.
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
WO2003037368A3 (en) Smad7 inhibitors for the treatment of cns diseases
WO2000001668A3 (en) Naaladase inhibitors useful as pharmaceutical compounds and compositions
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
CA2275167A1 (en) The topical use of kappa opioid agonists to treat ocular pain
WO2000002551A3 (en) Methods and compounds for treating depression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase